Long-term side effects of high-risk neuroblastoma survivors in a referral center in central Illinois.

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 129-129
Author(s):  
Beth Speckhart ◽  
Reuben Antony ◽  
Karen S. Fernandez
Keyword(s):  
Side Effects ◽  
High Risk ◽  
Term Therapy ◽  
Solid Organ ◽  
Long Term Effects ◽  
Improved Outcomes ◽  
Risk Patients ◽  
Central Illinois ◽  
Long Term Therapy

129 Background: Neuroblastoma (NBL) is the most common extra-cranial solid organ malignancy in children. Although low and intermediate-risk patients have a survival of close to 90%, the same cannot be said for patients with high risk (HR) disease. In the last decade multi-modality treatment of HR NBL patients has been intensified to include chemotherapy, surgery, radiation, bone marrow transplantation and immunotherapy and has resulted in improved survival (Yu, 2009). Data regarding the medium to long-term side effects of this intensive multi-modality therapy is now being collected as the population of HR neuroblastoma survivors continues to grow. Methods: We retrospectively reviewed the clinical data of survivors of HR NBL treated at the Children’s Hospital of Illinois diagnosed since 2009 and evaluated the long-term side effects of survivors through 2015. Results: We found 14 NBL patients of whom 10 had HR disease. Four patients died of progressive disease. Therapy-related, long-term side effects occurred in 6 patients: hearing loss (n = 6), adrenal insufficiency (n = 2), focal nodular hyperplasia of the liver (n = 2), linear growth retardation (n = 1). No patient in our cohort developed thyroid or cardiac problems and no patient was diagnosed with a second malignancy in the 5 years of observation. Conclusions: While the improved outcomes seen in HR NBL patients is encouraging, we found in our small cohort hat survivors of multimodality therapy for high-risk neuroblastoma experience significant long-term effects of treatment which impact their quality of life as well as growth and development. As the number of NBL survivors increases our understanding of the long-term therapy related side effects will continue to improve. Larger longitudinal studies are needed to monitor for other possible side effects that may manifest overtime such as cardiomyopathy, disturbances in sexual development, fertility, intellectual function, learning problems and therapy related second malignancies later in life.

Aspects of Long-Term Treatment with Neuroleptics Historical and Literature Review—Personal Experience with Fluspirilene and Penfluridol

1975 ◽  
Vol 3 (2) ◽  
pp. 114-124 ◽  
Author(s):  
Lucian Floru
Keyword(s):  
Side Effects ◽  
Literature Review ◽  
Personal Experience ◽  
Term Treatment ◽  
Term Therapy ◽  
Tabular Form ◽  
Long Term Effects ◽  
Long Term Treatment ◽  
Long Term Therapy

The literature on neuroleptics with substance-specific long-term effects (fluspirilene, penfluridol) is reviewed in tabular form. This is followed by a report of personal investigations on 76 schizophrenics who were treated with fluspirilene initially within the hospital and later on an out-patient basis, on 86 patients who were treated with it exclusively at the out-patients' department, as well as on 123 schizophrenic psychoses treated with penfluridol in the out-patients' department. The side-effects caused by the two substances are compared. Pre-requisites for effective long-term therapy with a few complications are discussed.

New opioid side effects and implications for long-term therapy

2011 ◽  
Vol 1 (1) ◽  
pp. 18-21 ◽  
Author(s):  
S. Raghavan ◽  
A.D. Harvey ◽  
S.R. Humble
Keyword(s):  
Side Effects ◽  
Term Therapy ◽  
Long Term Therapy

Slow-Release Terbutaline and Theophylline for the Long-Term Therapy of Children With Asthma: A Latin Square and Factorial Study of Drug Effects and Interactions

PEDIATRICS ◽  
1989 ◽  
Vol 84 (1) ◽  
pp. 119-125
Author(s):  
Olivia Kit Wun Chow ◽  
Kam Pui Fung
Keyword(s):  
Side Effects ◽  
Slow Release ◽  
Clinical Symptoms ◽  
Combined Therapy ◽  
Latin Square ◽  
Term Therapy ◽  
Long Term Effects ◽  
Long Term Treatment ◽  
Children With Asthma

To evaluate the long-term effects of slow-release formulations of theophylline and terbutaline on pulmonary function, clinical symptoms, and side effects, 24 children with stable and moderately severe perennial asthma participated in a prospective double-blind crossover study. The patients and the treatments were randomized according to the Latin square design to eliminate all possible period/climate biases throughout the protracted study period. The treatments consisted of terbutaline, 5 mg, theophylline, 200 mg, the combination, and placebo, given twice daily orally and crossing over every 28 days. The two drugs, administered alone or in combination, improved lung function and symptoms when compared with placebo. The interaction of theophylline and terbutaline was quantitatively shown by 2 x 2 factorial statistical design to be essentially additive rather than synergistic in the control of asthma. No increase in side effects was noted when the combined therapy was used. These findings suggest therapeutic advantages to combining submaximal oral doses of sustained-release theophylline and terbutaline for the long-term treatment of children with asthma.

A Ten-Year Assessment of Methicillin-Associated Side Effects

PEDIATRICS ◽  
1976 ◽  
Vol 58 (3) ◽  
pp. 329-334
Author(s):  
Martha D. Yow ◽  
Larry H. Taber ◽  
Fred F. Barrett ◽  
A. Aaron Mintz ◽  
G. Richard Blankinship ◽  
...  
Keyword(s):  
Side Effects ◽  
Great Majority ◽  
Incidence Rates ◽  
Term Therapy ◽  
Average Dose ◽  
True Incidence ◽  
Number Of Patients ◽  
Chemical Irritation ◽  
Long Term Therapy

The exact incidence and importance of side effects associated with methicillin therapy in children is unknown. During the ten-year period from 1964 to 1974 approximately 3,000 Houston children who received methicillin were observed for side effects. The great majority of these patients received the drug for less than ten days; however, side effects were more common in patients receiving long-term therapy. In order to assess these side effects, experiences with 124 children who received methicillin for ten days or longer were reviewed in depth. The average dose of methicillin was 200 mg/kg/day and the average duration was 22 days. In this highly selected group there were no adverse side effects in 54.8% and only eosinophilia in an additional 13%. Leukopenia occurred in 16%, microscopic hematuria in 8%, gross hematuria in 4%, skin rash in 6%, and "drug fever" in 6%. In many instances several of these side effects occurred within a single patient so that the total number of patients with definite side effects was 39 of 124 (31.5%). The true incidence figure of overall side effects is much lower than 31.5%. Corrected incidence rates based on a conservative figure of 3,000 methicillin-treated children are less than 1.5% for all side effects. In some patients the mechanism producing the adverse reactions seemed to be chemical irritation or toxicity and in others hypersensitivity. In nine of the 39 patients follow-up studies were not optimal. In the other 30 patients all side effects were reversible.

scholarly journals Long-Term Effects of Metformin and Lifestyle Modification on Nonalcoholic Fatty Liver Disease Obese Adolescents

2010 ◽  
Vol 2010 ◽  
pp. 1-6 ◽  
Author(s):  
Lian Tock ◽  
Ana R. Dâmaso ◽  
Aline de Piano ◽  
June Carnier ◽  
Priscila L. Sanches ◽  
...  
Keyword(s):  
Lifestyle Intervention ◽  
Lifestyle Modification ◽  
Subcutaneous Fat ◽  
Term Therapy ◽  
Long Term Effects ◽  
Nonalcoholic Fatty Liver ◽  
Obese Adolescents ◽  
Reduced Body ◽  
Long Term Therapy

Objective. To assess the long-term effects of metformin in combination with lifestyle intervention and its association between insulin levels and the degree of steatosis at ultrasonography (US) in obese adolescents.Methods. Thirty-five postpubertal obese boys were randomized into two groups: one receiving metformin in combination with a multidisciplinary lifestyle intervention versus a placebo group, which also received the same intervention. The visceral, subcutaneous fat and degree of steatosis were measured by ultrasonography. Fasting blood samples were collected to analyze glucose, insulin, insulin resistance, and aminotransferases. Repeated ANOVA measures were used to compare changes over time and between groups, and Spearman's correlations were used to identify an association between insulin and the degree of steatosis at US.Results. There was a positive correlation between the degree of steatosis at US with insulin concentrations and HOMA-IR. Long-term therapy plus metformin significantly reduced body weight, body mass index, insulin, HOMA-IR, and visceral fat.Conclusions. Metformin was more effective than the placebo in improving clinical parameters associated with obesity and steatosis.

scholarly journals Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Blood ◽  
2012 ◽  
Vol 120 (6) ◽  
pp. 1202-1209 ◽  
Author(s):  
Srdan Verstovsek ◽  
Hagop M. Kantarjian ◽  
Zeev Estrov ◽  
Jorge E. Cortes ◽  
Deborah A. Thomas ◽  
...  
Keyword(s):  
High Risk ◽  
Phase 1 ◽  
Cancer Center ◽  
Term Therapy ◽  
Long Term Outcomes ◽  
Jak2 Inhibitor ◽  
Significant Difference ◽  
Md Anderson ◽  
Long Term Therapy

Abstract Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF). We analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1/2 trial. After a median of 32 months of follow-up, 58 patients (54%) were still receiving ruxolitinib, with overall survival (OS) of 69%. The splenomegaly and symptom reductions achieved with ruxolitinib were sustained with long-term therapy. Therapy was well tolerated; discontinuation rates at 1, 2, and 3 years were 24%, 36%, and 46%, respectively. OS of 107 MDACC patients was significantly better (P = .005) than that of 310 matched (based on trial enrollment criteria) historical control patients, primarily because of highly significant difference in OS in the high-risk subgroup (P = .006). Furthermore, among MDACC patients, those with high-risk MF experienced the same OS as those with intermediate-2 risk. Patients with ≥ 50% reduction in splenomegaly had significantly prolonged survival versus those with < 25% reduction (P < .0001). Comparison of discontinuation rates and reasons for stopping the therapy to those reported for other 51 patients in the phase 1/2 trial, and 155 ruxolitinib-treated patients in phase 3 COMFORT-I study, suggest that continued therapy with ruxolitinib at optimal doses contributes to the benefits seen, including OS benefit.

scholarly journals Imaging in phenytoin induced neurotoxicity: a case series

2017 ◽  
Vol 6 (1) ◽  
pp. 355
Author(s):  
Manali Arora ◽  
Deb Kumar Boruah ◽  
Vishal Thakker ◽  
Sangeeta Bhanwra
Keyword(s):  
Side Effects ◽  
Megaloblastic Anemia ◽  
Cerebellar Atrophy ◽  
Case Series ◽  
Cerebral Atrophy ◽  
Term Therapy ◽  
Seizure Disorders ◽  
Anti Epileptic Drug ◽  
Long Term Therapy

Phenytoin is a commonly used anti-epileptic drug for various types of seizure disorders except for absent seizures. Long term dose dependant neurological side effects of phenytoin therapy include cerebellar atrophy, cerebral atrophy and brain stem atrophy. Skull hyperostosis, gum hypertrophy and megaloblastic anemia are other known effects of Long term therapy. We present four cases depicting clinical and neuroimaging findings of Phenytoin induced Toxicity.

Sign in / Sign up

Export Citation Format

Share Document